Benzinga | Mar 12, 2021 07:37AM EST

Baird Downgrades Quest Diagnostics to Neutral, Announces $137 Price Target

Baird analyst Eric Coldwell downgrades Quest Diagnostics (NYSE:DGX) from Outperform to Neutral and announces $137 price target.